Human cytomegalovirus-specific CD4+-T-cell cytokine response induces fractalkine in endothelial cells

Journal of Virology

Volumn 78, Issue 23, 2004, Pages 13173-13181

  Bolovan Fritts, Cynthia A ^a   Trout, Rodney N ^a   Spector, Stephen A ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; FRACTALKINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CELL DAMAGE; CELL INTERACTION; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; SEROLOGY; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS IMMUNITY; VIRUS PATHOGENESIS;

ANTIGENS, CD14; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHEMOKINES, CX3C; CYTOKINES; CYTOMEGALOVIRUS; ENDOTHELIAL CELLS; HUMANS; INTERFERON TYPE II; MEMBRANE PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8744223406     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.23.13173-13181.2004     Document Type: Article

References (43)

1. + monocytes. J. Exp. Med. 197:1701-1707.
2. Bettinotti, M. P., S. Solomon, M. Battiwala, N. Hensel, K. Ghazarian, D. Stroncek, and J. Barrett. 2003. T-cell response against the cytomegalovirus proteins pp65 and IE1. Hum. Immunol. 64:S73.
3. + memory T-cell response to CMV. J. Immunol. 167:1151-1163.
4. Bruning, J. H., M. C. Persoons, K. B. Lemstrom, F. S. Stals, E. De Clercq, and C. A. Bruggeman. 1994. Enhancement of transplantation-associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMPC. Transplant. Int. 7(Suppl. 1):S365-S370.
5. Compton, T., E. A. Kurt-Jones, K. W. Boehme, J. Belko, E. Latz, D. T. Golenbock, and R. W. Finberg. 2003. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J. Virol. 77:4588-4596.
6. Feng, L., S. Chen, G. E. Garcia, Y. Xia, M. A. Siani, P. Botti, C. B. Wilson, J. K. Harrison, and K. B. Bacon. 1999. Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int. 56:612-620.
7. Fraticelli, P., M. Sironi, G. Bianchi, D. D'Ambrosio, C. Albanesi, A. Stoppacciaro, M. Chieppa, P. Allavena, L. Ruco, G. Girolomoni, F. Sinigaglia, A. Vecchi, and A. Mantovani. 2001. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J. Clin. Investig. 107:1173-1181.
8. Garton, K. J., P. J. Gough, C. P. Blobel, G. Murphy, D. R. Greaves, P. J. Dempsey, and E. W. Raines. 2001. Tumor necrosis factor-converting enzyme (ADAM17) mediates cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276:37993-38001.
9. Gruhler, A., and K. Fruh. 2000. Control of MHC I traffic from the ER by cellular chaperones and viral anti-chaperones. Traffic 1:306-311.
10. Haskell, C. A., W. W. Hancock, D. J. Salant, W. Gao, V. Csizmadia, W. Peters, K. Faia, O. Fituri, J. B. Rottman, and I. F. Charo. 2001. Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection. J. Clin. Investig. 108:679-688.
11. Hensel, N., J. J. Melenhorst, K. Bradstock, A. P. Schwarer, R. Eniale, R. Nakamura, and A. J. Barrett. 2002. Flow cytometric quantitation and characterization of the T-lymphocyte memory response to CMV in healthy donors. Cytotherapy 4:29-40.
12. Hosenpud, J. D., G. D. Shipley, and C. R. Wagner. 1992. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J. Heart Lung Transplant. 11:9-23.
13. Kledal, T. N., M. M. Rosenkilde, and T. W. Schwartz. 1998. Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28. FEBS Lett. 441:209-214.
14. Lemstrom, K., R. Sihvola, C. Bruggeman, P. Hayry, and P. Koskinen. 1997. Cytomegalovirus-infection enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation 95:2614-2616.
15. Lemstrom, K., P. Koskinen, L. Krogerus, M. Daemen, C. A. Bruggeman, and P. J. Hayry. 1995. Cytomegalovirus antigen expression, endotheliaocell proliferation, and intimai thickening in rat cardiac allografts. Circulation 92:2594-2604.
16. Lemstrom, K. B., J. H. Bruning, C. A. Bruggeman, P. Koskinen, P. T. Aho, S. Yilmaz, I. T. Lautenschlager, and P. J. Hayry. 1994. Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. Circulation 90:1969-1978.
17. Lemstrom, K., J. Bruning, P. Koskinen, C. A. Bruggeman, I. Lautenschlager, and P. Hayry. 1994. Triple-drug immunosuppression significantly reduces chronic rejection in noninfected and RCMV-infected rats. Transplant. Proc. 26:1727-1728.
18. Lemstrom, K. B., J. H. Bruning, C. A. Bruggeman, I. T. Lautenschlager, and P. J. Hayry. 1993. Cytomegalovirus infection enhances smooth muscle cell proliferation and intimal thickening of rat aortic allografts. J. Clin. Investig. 92:549-558.
19. Margulies, B. J., H. Browne, and W. Gibson. 1996. Identification of the human cytomegalovirus G protein coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles. Virology 225:111-125.
20. McDermott, D. H., J. P. Halcox, W. H. Schenke, M. A. Waclawiw, M. N. Merrell, N. Epstein, A. A. Quyyumi, and P. M. Murphy. 2001. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ. Res. 89:401-407.
21. Merigan, T. C., D. G. Renlund, S. Keay, et al. 1992. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N. Engl. J. Med. 326:1182-1186.
22. Mocarski, E. S., Jr., and C. T. Courcelle. 2001. Cytomegaloviruses and their replication, p. 2629-2674. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott/The Williams & Wilkins Co., Philadelphia, Pa.
23. Orloff, S. L. 1999. Elimination of donor-specific alloreactivity by bone marrow chimerism prevents cytomegalovirus accelerated transplant vascular sclerosis in rat small bowel transplants. J. Clin. Virol. 12:G23-G25.
24. Penfold, M. E., D. J. Dairaghi, G. M. Duke, N. Saederup, E. S. Mocarski, G. W. Kemble, and T. J. Schall. 1999. Cytomegalovirus encodes a potent alpha chemokine. Proc. Natl. Acad. Sci. USA 96:9839-9844.
25. Penfold, M. E. T., T. L. Schmidt, D. J. Dairaghi, P. A. Barry, and T. J. Schall. 2003. Characterization of the rhesus cytomegalovirus US28 locus. J. Virol. 77:10404-10413.
26. Prichard, M. N., M. E. Penfold, G. M. Duke, R. R. Spaete, and G. W. Kemble. 2001. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev. Med. Virol. 11:191-200.
27. 3CR1) in cardiac allograft rejection. J. Immunol. 165:6067-6072.
28. Saederup, N., S. A. Aguirre, T. E. Sparer, D. M. Bouley, and E. S. Mocarski. 2001. Murine CMV CC chemokine homolog MCK-2 (m131-129) is a determinant of dissemination that increases inflammation at initial sites of infection. J. Virol. 75:9966-9976.
29. Saederup, N., Y. C. Lin, D. J. Dairaghi, T. J. Schall, and E. S. Mocarski. 1999. Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host. Proc. Natl. Acad. Sci. USA 96:10881-10886.
30. Simmen, K. A., J. Singh, B. G. Luukkonen, M. Lopper, A. Bittner, N. E. Miller, M. R. Jackson, T. Compton, and K. Fruh. 2001. Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B. Proc. Natl. Acad. Sci. USA 98:7140-7145.
31. Speir, E., Modali, R., Huang, E-S, Leon, M. B., Shawl, F., Finkel, T., and S. E. Epstein. 1994. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265:391-394.
32. Streblow, D. N., C. Kreklywich, Q. Yin, V. T. dela Melena, C. L. Corless, P. A. Smith, C. Brakebill, J. W. Cook, C. Vink, C. A. Bruggeman, J. A. Nelson, and S. L. Orloff. 2003. Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J. Virol. 77:2182-2194.
33. Streblow, D. N., C. Soderberg-Naucler, J. Vieira, P. Smith, E. Wakabayashi, F. Ruchti, K. Mattison, Y. Altschuler, and J. A. Nelson. 1999. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99:511-520.
34. Umehara, H., E. T. Bloom, T. Okazaki, N. Domae, and T. Imai. 2001. Fractalkine and vascular injury. Trends Immunol. 22:602-607.
35. Umehara, H., and T. Imai. 2001. Role of fractalkine in leukocyte adhesion and migration and in vascular injury. Drug News Perspect. 14:460-464.
36. Umehara, H., E. T. Bloom, T. Okazaki, Y. Nagano, O. Yoshie, and T. Imai. 2003. Fractalkine in vascular biology. Arterioscler. Thromb. Vasc. Biol. 23:1-8.
37. Valantine, H. A., S.-Z. Gao, S. G. Menon, D. G. Renlund, S. A. Hunt, M. D., P. Oyer, E. B. Stinson, B. W. Brown, T. C. Merigan, and J. S. Schroeder. 1999. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 100:61-66.
38. Vieira, J., T. J. Schall, L. Corey, and A. P. Geballe. 1998. Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene. J. Virol. 72:8158-8165.
39. Waldman, W. J., J. D. LeClaire, and D. A. Knight. 2002. T-cell activation response to allogenic CMV-infected endothelial cells is not prevented by ganciclovir or foscarnet: implications for transplant vascular sclerosis. Transplantation 73:314-318.
40. Wong, B. W., D. Wong, and B. M. McManus. 2002. Characterization of fractalkine (CX3CL1) and CX3R1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular diseases. Cardiovasc. Pathol. 11:332-338.
41. Yoneda, O., T. Imai, S. Goda, H. Inoue, A. Yamauchi, T. Okazaki, H. Imai, O. Yoshie, E. T. Bloom, N. Domae, and H. Umehara. 2000. Fractalkine-mediated endothelial cell injury by NK cells. J. Immunol. 164:4055-4062.
42. Zhu, J., G. M. Shearer, J. E. Norman, L. A. Pinto, F. M. Marincola, A. Prasad, M. A. Waclawiw, G. Csako, A. A. Quyyumi, and S. E. Epstein. 2000. Host response to cytomegalovirus infection as a determinant of susceptibility to coronary artery disease: sex-based differences in inflammation and type of immune response. Circulation 102:2491-2496.
43. Zhou, Y. F., M. B. Leon, M. W. Waclawiw, J. J. Popma, Z. X. Yu, T. Finkel, and S. E. Epstein. 1996. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N. Engl. J. Med. 335:624-630.